ELVN: Rounding Bottom detected on 31 Mar 2026

ELVN is displaying a textbook rounding bottom formation, a reversal pattern characterized by a gradual price recovery from depressed lows. The pattern exhibits solid structural quality (13.75/15), strong volume confirmation (12.0/12), and a reliable breakout score (13.0/13), combining for an overall pattern quality score of 38.75/40. Price has recovered from key support at $14.78 to current $36.59—a 147% move—now testing resistance at $23.00. The conservative target stands at $39.03. Volume surge to 2.0M shares (29% above average) supports breakout conviction, with RSI at 66.68 indicating strength without extreme overbought extremes. Win probability scores 64.22%, reflecting meaningful upside probability.

On January 8, 2026, Enliven reported positive initial Phase 1b data from the ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors. The company achieved a cumulative major molecular response rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts. Management is preparing for upcoming FDA regulatory interactions to align on dose selection and support initiation of the Phase 3 trial in the second half of 2026. As of December 31, 2025, the company had cash totaling $462.6 million, providing cash runway into the first half of 2029. The near-term catalyst environment is exceptionally bullish: Merck's $6.7 billion acquisition of Terns Pharmaceuticals validated strong demand in the chronic myeloid leukemia market, estimated at $9 billion globally, and Mizuho raised its price target to $45 with outperform rating, while HC Wainwright lifted its target to $56 with a Buy rating. The rounding bottom pattern forms at an inflection point where positive Phase 1b data and analyst upgrades have fueled 124% three-month gains.

A successful breakout above the $23.00 resistance would target $39.03 (conservative target), representing approximately 6.6% upside from current levels at $36.59. The pattern's strength relies on sustained volume above the 1.55M daily average—today's 2.0M shares (1.29x ratio) demonstrates adequate participation. The invalidation point sits at $14.78 support; a breakdown through this level would signal pattern failure and negate the reversal thesis. The setup's 64.22% win probability reflects historical rounding bottom efficacy and the strong technical backdrop. Breakout confirmation typically requires two consecutive closes above resistance with volume support; the pattern suggests the measured move extends to $39.03, but rallies to $41-43 are structurally plausible if momentum accelerates post-breakout.

Chief Medical Officer Helen Collins sold 40,000 shares on March 9-10, 2026, reducing her holdings by 61.54%, signaling potential insider concerns despite public optimism. Q4 2025 loss of $0.48 per share exceeded analyst expectations of $0.39, indicating execution pressure despite positive clinical narrative. The healthcare sector operates in a bearish regime (regime score -0.41), and the broader market regime is bearish (-0.59), which could limit upside participation if sentiment shifts. RSI at 66.68 approaches overbought threshold (70), suggesting limited room for further appreciation without a pullback. ELVN-001's 47% major molecular response rate at 24 weeks trails Tern's TERN-701 at 74%, creating competitive risk if Phase 3 trials underperform relative expectations. The stock's 3-month gain of 124% and recent surge exposes high momentum-driven positions vulnerable to profit-taking. Clinical development remains speculative—Phase 3 initiation is planned for H2 2026, meaning months of regulatory uncertainty ahead before pivotal results. Finally, high volatility (20-day volatility 86.63%) amplifies downside whipsaw risk if clinical milestones disappoint or adverse data emerges.